Health Care

Explore how Bristol‑Myers Squibb’s S&P 500 rank slip and new congressional probe could affect its valuation, pipeline, and market strategy.

European markets ended the week down, yet a French optical‑products firm rose over 5% amid U.S. diplomatic uncertainty, rate hikes and a paused tech rally.

Discover EISAI’s breakthrough glioma therapy—FDA‑designated, biomarker‑driven, and showing early disease stabilization with a favorable safety profile.

Roche’s new drug divarasib beats current KRAS G12C inhibitors in a Phase‑III trial, improving survival in NSCLC while keeping safety unchanged.

Regeneron’s partnership with the 100 Black Men of America conference shows how pharma’s community engagement drives brand equity, payer wins and higher patient value.

Labcorp Holdings Inc. (LH) confirms Q2 2026 earnings will be released July 30, highlighting regulatory compliance, global reach, and insider activity.

Intuitive Surgical’s da Vinci 5 drives 11,000‑unit growth, boosting revenue, earnings and market leadership in surgical robotics.

Argenx & Halozyme reshape advanced therapeutics: high‑margin biologics meet delivery tech, boosting value‑based pricing and investor confidence.

Siemens Healthineers leads oncology pre‑clinical research, delivering advanced imaging, PK/PD, biomarker, and toxicology services that speed cancer drug development and improve patient outcomes.

Fresenius SE’s €1 billion dual‑tranche bond deal uses a €500 m 3.375 % 2031 and €3.75 % 2034 tranche, with ING’s pre‑stabilisation to secure low‑cost refinancing and ESG‑ready growth.